|
|
|
|
130
|
Mon, 7/29/2019,
8:30 AM -
10:20 AM
|
CC-112
|
|
Statistical Methods for Time-To-Event Data and Applications — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Ruvie Martin, Novartis Pharmaceuticals
|
|
8:35 AM
|
Tools to Compare Restricted Mean Survival Times in Randomized Controlled Studies with Small Sample Data
Miki Horiguchi, Kitasato University; Hajime Uno, Dana-Farber Cancer Institute
|
|
8:50 AM
|
Survival Analysis in the Absence of Proportional Hazards: Defining the Relevant Null Hypothesis
Steven Snapinn, Alder Biopharmaceuticals; Qi Jiang, Seattle Genetics
|
|
9:05 AM
|
Modeling the Impact of Dose Intervention on Time-To-Event Outcomes
Amir Nikooienejad, Eli Lilly and Company; Yongming Qu, Eli Lilly and Company
|
|
9:20 AM
|
A Flexible Parametric Survival Model for Fitting Time-to-Event Data in Clinical Trials
Jason Liao, Merck & Co. Inc.; Frank G Liu, Merck Sharp & Dohme Inc.
|
|
9:35 AM
|
Teasing Out the Overall Survival Benefit with Adjustment for Treatment Switching to Other Therapies
Meijing Wu, AbbVie; Weili He, AbbVie; Qiming Liao, VIIV Health Care; Yabing Mai, AbbVie
|
|
9:50 AM
|
An Approach to Increase Power in Immuno-Oncology Trials When Non-Proportional Hazard Is Present
Nan Jia, Sanofi US
|
|
10:05 AM
|
Evaluating Methods for Correcting the Impact of Treatment Switching on Overall Survival
Jin Zhang
|
